Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

Valeant steps up pressure on Allergan with raised bid

Ups price yet again in attempt to acquire company behind Botox

- PMLiVE

GSK and Bayer strike new biotech cancer deals

Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines

- PMLiVE

Youssef Bennani to chair Domain Therapeutics

He is VP R&D at Vertex

- PMLiVE

Hepatitis C therapies: dawn of a new age

New treatments from the likes of Merck & Co, Janssen and Gilead offer significant treatment advances

- PMLiVE

GSK plans to sell off older products

Invites bids for mature brands as part of move to focus on growth areas

UK flag

Lilly invests in UK life sciences via biotech fund

Will support work of UK universities

National Institute for Health and Care Excellence NICE logo

NICE denies Stelara’s use in psoriatic arthritis

Refuses to extend NHS-recommended indications of Janssen drug

- PMLiVE

Parexel appoints chief scientific officer

Promotion for Sy Pretorius

- PMLiVE

New digital head for Just:: Health

Daniel Prideaux specialises in multichannel marketing

- PMLiVE

UK NHS to use pharmacy scratch card

West Yorkshire’s community pharmacies aims to improve medicines optimisation

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links